3,4-disubstituted 1H-pyrazole compounds and their use as...

Details 3,4-disubstituted 1H-pyrazole compounds and their use as... 3,4-disubstituted 1H-pyrazole compounds and their use as...

2007-10-19

2010-11-02

Havlin, Robert (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S244000

Reexamination Certificate

active

07825140

ABSTRACT:
The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3.In formula (0):X is a group R1-A-NR4— or a 5- or 6-membered carbocyclic or heterocyclic ring;A is a bond, SO2, C═O, NRg(C═O) or O(C═O) wherein Rgis hydrogen or C1-4hydrocarbyl optionally substituted by hydroxy or C1-4alkoxy;Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length;R1is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C1-4hydrocarbyloxy, amino, mono- or di-C1-4hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO2;R2is hydrogen; halogen; C1-4alkoxy (e.g. methoxy); or a C1-4hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4alkoxy (e.g. methoxy);R3is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; andR4is hydrogen or a C1-4hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4alkoxy (e.g. methoxy).

REFERENCES:
patent: 4282361 (1981-08-01), Hecht et al.
patent: 4950668 (1990-08-01), Okada et al.
patent: 6066738 (2000-05-01), Dinsmore et al.
patent: 7385059 (2008-06-01), Berdini et al.
patent: 2002/0091116 (2002-07-01), Zhu et al.
patent: 2004/0087798 (2004-05-01), Yamada
patent: 2004/0116399 (2004-06-01), Zhu et al.
patent: 2004/0214870 (2004-10-01), Xin et al.
patent: 2005/0119305 (2005-06-01), Naka et al.
patent: 2008/0139620 (2008-06-01), Wyatt et al.
patent: 2008/0161251 (2008-07-01), Curry et al.
patent: 2008/0161355 (2008-07-01), Curry et al.
patent: 2008/0194562 (2008-08-01), Wyatt et al.
patent: 2008/0269207 (2008-10-01), Berdini et al.
patent: 2008/0306069 (2008-12-01), Wyatt et al.
patent: 2009/0012124 (2009-01-01), Wyatt et al.
patent: 2009/0036435 (2009-02-01), Curry et al.
patent: 2009/0142337 (2009-06-01), Squires
patent: 0947500 (1999-10-01), None
patent: 1348707 (2003-10-01), None
patent: 1642594 (2006-04-01), None
patent: WO94/13643 (1994-06-01), None
patent: 9849166 (1998-11-01), None
patent: 9852941 (1998-11-01), None
patent: 9932477 (1999-07-01), None
patent: 00/62778 (2000-10-01), None
patent: 01/02385 (2001-01-01), None
patent: 01/19798 (2001-03-01), None
patent: 0119788 (2001-03-01), None
patent: 01/58869 (2001-08-01), None
patent: 01/64642 (2001-09-01), None
patent: 0164643 (2001-09-01), None
patent: 01/98290 (2001-12-01), None
patent: 02/00651 (2002-01-01), None
patent: 02/18346 (2002-03-01), None
patent: 02/22601 (2002-03-01), None
patent: 02/051810 (2002-07-01), None
patent: 02/062804 (2002-08-01), None
patent: 02/064586 (2002-08-01), None
patent: WO02/066470 (2002-08-01), None
patent: 02/070483 (2002-09-01), None
patent: 02074312 (2002-09-01), None
patent: 02074774 (2002-09-01), None
patent: WO02/068406 (2002-09-01), None
patent: 02101007 (2002-12-01), None
patent: 03/011287 (2003-02-01), None
patent: 03/020217 (2003-03-01), None
patent: 03018536 (2003-03-01), None
patent: 03024448 (2003-03-01), None
patent: 03/048081 (2003-06-01), None
patent: 03/048158 (2003-06-01), None
patent: 03082872 (2003-10-01), None
patent: 2004/085385 (2004-10-01), None
patent: 2004/099127 (2004-11-01), None
patent: WO2005/002552 (2005-01-01), None
patent: 2005058881 (2005-06-01), None
patent: 2007/129062 (2007-11-01), None
patent: 2007/129066 (2007-11-01), None
patent: 2008/001101 (2008-01-01), None
patent: 2008/007113 (2008-01-01), None
patent: 2008/007122 (2008-01-01), None
patent: 2008/007123 (2008-01-01), None
patent: 2008/009954 (2008-01-01), None
patent: 2008/044041 (2008-04-01), None
Voskoglou-Nomikos et al. (Clin. Cancer Res, (2003), v. 9, p. 4227-39).
Zips et al. (In Vivo, vol. 19, p. 1-8, 2005).
Berdini et al., U.S. Appl. No. 11/875,470; “3,4-Disubstituted 1H-Pyrazole Compounds And Their Use As Cyclin Dependent Kinase And Glycogen Synthase Kinase-3 Modulators”; filed Oct. 19, 2007.
Statement of Relevance for foreign patent documents PCT WO 01/02385 (in French) and PCT WO 02/051810 (in German) already listed in the Information Disclosure Statement filed Nov. 7, 2007.
Notice of Allowance and Issue Fee Due dated Aug. 9, 2007 from U.S. Appl. No. 11/336,599.
Wyatt et al., “Identification of N-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design.” Journal of Medicinal Chemistry, vol. 51, No. 16, pp. 4986-4999, (2008).
Squires et al., “Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.” Molecular Cancer Therapeutics: vol. 8(2). pp. 324-332, (2009).
Voskoglou-Nomikos et al., “Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models.” Clinical Cancer Research, vol. 9, pp. 4227-4239, (2003).
Vippagunta et al.: Crystalline Solids,Advanced Drug Delivery Reviews. 48, pp. 3-26, (2001).
Patani et al.: Chem. Rev., 96, pp. 3147-3176, (1996).
Kislyi, et al., Hydrogenation on Granular Palladium-containing Catalysts: II. Hydrogenation of Nitroheterocyclic Compounds, Russian Journal of Organic Chemistry (2002), 38(2), 269-271 (Translation of Zhurnal Organicheskoi Khimii (2002), 38(2) 290-293).

Affiliated with

Also associated with

Rating

3,4-disubstituted 1H-pyrazole compounds and their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 3,4-disubstituted 1H-pyrazole compounds and their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3,4-disubstituted 1H-pyrazole compounds and their use as... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4251071